研报掘金丨国泰海通：维持梅花生物“增持”评级，目标价13.44元

Core Viewpoint - MeiHua Bio will actively respond to lawsuits and accelerate its overseas expansion [1] Company Valuation - The report from Guotai Junan Securities indicates that, considering the company's profitability is lower than comparable companies, a certain valuation discount is applied [1] - A price-to-earnings (PE) ratio of 11.79 times is projected for the year 2025 [1]